Eagle Pharmaceuticals (EGRX)

Eagle Pharmaceuticals Inc (EGRX) Q3 2020 Earnings Call Transcript
Nov. 2, 2020 | Price: Free! | Source: Motley Fool

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q3 2020 Results - Earnings Call Transcript
Nov. 2, 2020 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals Inc (EGRX) Q2 2020 Earnings Call Transcript
Aug. 10, 2020 | Price: Free! | Source: Motley Fool

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q2 2020 Results - Earnings Call Transcript
Aug. 10, 2020 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q1 2020 Results - Earnings Call Transcript
May 11, 2020 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals Inc (EGRX) Q1 2020 Earnings Call Transcript
May 11, 2020 | Price: Free! | Source: Motley Fool

Eagle Pharmaceuticals Inc (EGRX) Q4 2019 Earnings Call Transcript
March 2, 2020 | Price: Free! | Source: Motley Fool

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q4 2019 Results - Earnings Call Transcript
March 2, 2020 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals Inc (EGRX) Q3 2019 Earnings Call Transcript
Nov. 12, 2019 | Price: Free! | Source: Motley Fool

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q3 2019 Results - Earnings Call Transcript
Nov. 12, 2019 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals Inc (EGRX) Q2 2019 Earnings Call Transcript
Aug. 9, 2019 | Price: Free! | Source: Motley Fool

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q2 2019 Results - Earnings Call Transcript
Aug. 9, 2019 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q1 2019 Results - Earnings Call Transcript
May 7, 2019 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q4 2018 Results - Earnings Call Transcript
Feb. 28, 2019 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals Inc. (EGRX) CEO Scott Tarriff on Q3 2018 Results - Earnings Call Transcript
Nov. 1, 2018 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals Inc. (EGRX) CEO Scott Tarriff on Q2 2018 Results - Earnings Call Transcript
Aug. 7, 2018 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q1 2018 Results - Earnings Call Transcript
May 10, 2018 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q4 2017 Results - Earnings Call Transcript
Feb. 26, 2018 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q3 2017 Results - Earnings Call Transcript
Nov. 8, 2017 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q2 2017 Results - Earnings Call Transcript
Aug. 9, 2017 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q1 2017 Results - Earnings Call Transcript
May 8, 2017 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q4 2016 Results - Earnings Call Transcript
March 1, 2017 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q3 2016 Results - Earnings Call Transcript
Nov. 9, 2016 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q2 2016 Results - Earnings Call Transcript
Aug. 9, 2016 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q1 2016 Results - Earnings Call Transcript
May 9, 2016 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q4 2015 Results - Earnings Call Transcript
Feb. 25, 2016 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q3 2015 Results - Earnings Call Transcript
Nov. 11, 2015 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q2 2015 Results - Earnings Call Transcript
Aug. 11, 2015 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q1 2015 Results - Earnings Call Transcript
May 18, 2015 | Price: Free! | Source: Seeking Alpha

Eagle Pharmaceuticals' (EGRX) CEO Scott Tarriff on Q4 2014 Results - Earnings Call Transcript
Dec. 17, 2014 | Price: Free! | Source: Seeking Alpha

Recent filings

Eagle Pharmaceuticals's Chief Financial Officer just declared owning 15,286 shares of Eagle Pharmaceuticals - Nov. 9, 2020

Eagle Pharmaceuticals's Chief Medical Officer was just granted 35,000 options - Nov. 2, 2020

Eagle Pharmaceuticals Just Filed Its Quarterly Report: Earnings Per Share B... - Nov. 2, 2020

Eagle Pharmaceuticals's Chief Medical Officer just declared ownership of no shares of Eagle Pharmaceuticals - Nov. 2, 2020

Eagle Pharmaceuticals Reports Third Quarter 2020 Results - Nov. 2, 2020

Changes in - Oct. 1, 2020

Confidential © 2020 Eagle Pharmaceuticals, Inc. All Rights Reserved. Eagle Pharmaceuticals Nasdaq: Egrx September 2020 - Sept. 28, 2020

Eagle Pharmaceuticals Commences $25 Million Accelerated Share Repurchase As Part Of Existing $160 Million Share Repurchase Program - Sept. 24, 2020

Eagle Pharmaceuticals’ Japanese Licensing Partner, Symbio, Receives Approval Of Treakisym Ready-To-Dilute (“Rtd”) Formulation, With Launch Expected In January 2021 - Sept. 23, 2020

Current report, items 7.01 and 9.01 - Sept. 14, 2020

Steven Boyd just provided an update on share ownership of Eagle Pharmaceuticals - Sept. 10, 2020

Eagle Pharmaceuticals Reports Second Quarter 2020 Results - Aug. 10, 2020

Eagle Pharmaceuticals Just Filed Its Quarterly Report: Earnings Per Share B... - Aug. 10, 2020

Departure of Directors or Certain - Aug. 6, 2020

Departure of Directors or Certain - July 16, 2020

Cms Establishes Unique J-Code For Eagle Pharmaceuticals’ Pemfexy™ (Pemetrexed For Injection) - July 9, 2020

Submission of Matters to a Vote of Security - June 29, 2020

Current report, items 7.01 and 9.01 - June 1, 2020

Eagle: Soliciting Material Under §240.14A-12 Eagle Pharmaceuticals, Inc. - May 22, 2020

Current report, items 7.01 and 9.01 - May 19, 2020

Eagle Pharmaceuticals Reports First Quarter 2020 Results - May 11, 2020

Eagle Pharmaceuticals Just Filed Its Quarterly Report: Earnings Per Share B... - May 11, 2020

Eagle Pharmaceuticals Advances Novel And Proprietary Formulation Of Fulvestrant Product Candidate Ea-114; Company To Request Additional Meeting With U.S. Food And Drug Administration (“Fda”) - May 4, 2020

Other definitive proxy statements - April 29, 2020

Eagle: Soliciting Material Under §240.14A-12 Eagle Pharmaceuticals, Inc. - April 29, 2020

Court Issues Favorable Patent Litigation Decision For Eagle Pharmaceuticals, Inc. And Teva Pharmaceutical Industries Ltd. For - April 28, 2020

Eagle Pharmaceuticals Announces Laboratory Test Results Demonstrating In Vitro - April 16, 2020

Share Repurchase - March 17, 2020

On March - March 16, 2020

Eagle Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Results - March 2, 2020

Eagle Pharmaceuticals Just Filed Its Annual Report: Earnings Per ShareBa... - March 2, 2020

STATE STREET CORPORATION just provided an update on share ownership of Eagle Pharmaceuticals - Feb. 14, 2020

Statement of acquisition of beneficial ownership by individuals - Feb. 14, 2020

Janus Henderson Group plc EIN just provided an update on share ownership of Eagle Pharmaceuticals - Feb. 13, 2020

Eagle Pharmaceuticals Receives Final Fda Approval For Pemfexy - Feb. 10, 2020

BlackRock, Inc. just provided an update on share ownership of Eagle Pharmaceuticals - Feb. 4, 2020

Eagle Pharmaceuticals's Chief Financial Officer just disposed of 1,653 shares - Jan. 27, 2020

Eagle Pharmaceuticals's Pres. & Chief Comm. Officer just disposed of 1,793 shares - Jan. 27, 2020

Major owner of Eagle Pharmaceuticals just disposed of 7,548 shares - Jan. 27, 2020

Eagle Pharmaceuticals's EVP and Chief Medical Officer just disposed of 1,630 shares - Jan. 27, 2020

Eagle Pharmaceuticals, Inc. just provided an update on share ownership of Eagle Pharmaceuticals - Jan. 17, 2020

Douglas L. Braunstein just provided an update on activist position in Eagle Pharmaceuticals - Jan. 16, 2020

Eagle: Cns/Metabolic Critical Care Pipeline Opportunities 10 - Jan. 13, 2020

Eagle Pharmaceuticals Resubmits Nda For Ryanodex For Exertional Heat Stroke - Jan. 9, 2020

Entry into a Material Definitive - Jan. 8, 2020

Major owner of Eagle Pharmaceuticals just picked up 58,300 shares - Jan. 7, 2020

Eagle Pharmaceuticals director was just granted 10,000 options - Jan. 7, 2020

Eagle Pharmaceuticals director was just granted 10,000 options - Jan. 7, 2020

Eagle Pharmaceuticals director was just granted 10,000 options - Jan. 7, 2020

Eagle Pharmaceuticals director was just granted 10,000 options - Jan. 7, 2020

Eagle Pharmaceuticals's EVP and Chief Medical Officer just picked up 23,185 shares - Jan. 7, 2020

Eagle Pharmaceuticals's Chief Financial Officer just picked up 18,868 shares - Jan. 7, 2020

Eagle Pharmaceuticals's Pres. & Chief Comm. Officer just picked up 20,596 shares - Jan. 7, 2020

Tyme Technologies And Eagle Pharmaceuticals Announce Strategic Collaboration To Advance Innovative Oral Sm-88 For The Treatment Of Patients With Cancer - Jan. 7, 2020

Eagle Pharmaceuticals director was just granted 10,000 options - Jan. 7, 2020

Entry into a Definitive Material - Dec. 19, 2019

Current report, items 7.01 and 9.01 - Dec. 17, 2019

Departure of Directors or Certain - Dec. 16, 2019

Eagle Pharmaceuticals Granted Orphan Drug Designation For Ryanodex - Dec. 16, 2019

Eagle Pharmaceuticals Just Received a Notice of Effectiveness - Dec. 16, 2019

Eagle Pharmaceuticals Reaches Settlement Agreement With Eli Lilly For Pemfexy (Pemetrexed For Injection) - Dec. 16, 2019

Following additional communications with the - Dec. 10, 2019

Eagle Pharmaceuticals Commences Dosing In Pilot Study For Novel Estrogen Receptor Antagonist Product Candidate - Dec. 9, 2019

Registration statement under Securities Act of 1933 - Nov. 15, 2019

Eagle Pharmaceuticals Announces Departure Of Douglas L. Braunstein From Board Of Directors - Nov. 14, 2019

Eagle Pharmaceuticals Reports Third Quarter 2019 Results - Nov. 12, 2019

Eagle Pharmaceuticals Just Filed Its Quarterly Report: Earnings Per Share B... - Nov. 12, 2019

Eagle Pharmaceuticals director just disposed of 16,931 shares - Oct. 28, 2019

Eagle Pharmaceuticals director just disposed of 10,616 shares - Oct. 23, 2019

Eagle: Transforming Patient Care By Targeting Best - In - Class Solutions - Oct. 21, 2019

Eagle Pharmaceuticals director just disposed of 15,544 shares - Oct. 18, 2019

Eagle Pharmaceuticals director just disposed of 28,038 shares - Oct. 15, 2019

Election of - Oct. 11, 2019

Eagle Pharmaceuticals director was just granted 10,000 options - Oct. 10, 2019

Eagle Pharmaceuticals director just disposed of 6,459 shares - Oct. 9, 2019

Eagle Pharmaceuticals’ Japanese Licensing Partner Symbio Announces Its Submission Of A New Drug Application For Treakisym Ready-To-Dilute Formulation - Oct. 7, 2019

Eagle Pharmaceuticals October 2019 © 2019 Eagle Pharmaceuticals, Inc. All Rights Reserved - Oct. 2, 2019

Eagle Pharmaceuticals director just disposed of 100 shares - Sept. 19, 2019

Eagle Pharmaceuticals director just disposed of 1,312 shares - Sept. 13, 2019

Eagle Pharmaceuticals director just declared ownership of no shares of Eagle Pharmaceuticals - Sept. 5, 2019

Election of - Sept. 3, 2019

Eagle Pharmaceuticals, Inc. Reports Second Quarter 2019 Results - Aug. 8, 2019

Eagle Pharmaceuticals Just Filed Its Quarterly Report: Earnings Per Share B... - Aug. 8, 2019

Eagle Pharmaceuticals Announces Clinical Development Plan Of Innovative Product Intended To Deliver Maximum Estrogen Receptor Inhibition In Patients With Estrogen Receptor (Er)-Positive Breast Cancer - Aug. 5, 2019

Submission of Matters to a Vote of Security - June 21, 2019

Eagle Pharmaceuticals June 2019 © 2019 Eagle Pharmaceuticals, Inc. All Rights Reserved - June 4, 2019

Eagle Pharmaceuticals May 2019 © 2019 Eagle Pharmaceuticals, Inc. All Rights Reserved 1 - May 22, 2019

Douglas L. Braunstein just provided an update on activist position in Eagle Pharmaceuticals - May 14, 2019

Eagle Pharmaceuticals director just disposed of 159,223 shares - May 13, 2019

Eagle Pharmaceuticals May 2019 © 2019 Eagle Pharmaceuticals, Inc. All Rights Reserved 1 - May 8, 2019

Eagle Pharmaceuticals Announces Positive Results Of A Study Conducted In Partnership With The U.S. Military To Evaluate Neuroprotective Effects Of Ryanodex For The Treatment Of Nerve Agent Exposure - May 7, 2019

Eagle Pharmaceuticals, Inc. Reports First Quarter 2019 Results - May 7, 2019

Eagle Pharmaceuticals Just Filed Its Quarterly Report: Earnings Per Share B... - May 7, 2019

Eagle: Soliciting Material Under §240.14A-12 Eagle Pharmaceuticals, Inc. - April 30, 2019

Other definitive proxy statements - April 30, 2019

Eagle Pharmaceuticals, Inc. Expands Licensing Agreement For Bendeka™ With Teva Pharmaceuticals International Gmbh - April 15, 2019

Major owner of Eagle Pharmaceuticals just disposed of 24,975 shares - April 3, 2019

Eagle Pharmaceuticals director just picked up 2,340 shares - March 6, 2019

Eagle Pharmaceuticals director just picked up 2,136 shares - March 6, 2019

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2018 Results - Feb. 28, 2019

Sorry, no schedule available for this company

Owner Shares% of PortfolioAs Of
1. ProQuest Associates IV LLC 3,652,284 0.9 June 30, 2017
2. HENDERSON GROUP PLC 1,706,644 N/A June 30, 2020
3. JANUS CAPITAL MANAGEMENT LLC 1,454,778 0.1 March 31, 2017
4. Peter S. Park 1,260,611 N/A April 5, 2016
5. Park West Asset Management LLC 1,120,235 2.5 June 30, 2020
6. State Street Corp 779,797 N/A June 30, 2020
7. State Street Corp 779,797 N/A June 30, 2020
8. BlackRock Fund Advisors 769,869 N/A Sept. 30, 2016
9. VANGUARD GROUP INC 760,103 N/A Sept. 30, 2019
10. VANGUARD GROUP INC 760,103 N/A Sept. 30, 2019
11. VANGUARD GROUP INC 753,474 N/A June 30, 2019
12. VANGUARD GROUP INC 739,802 N/A March 31, 2020
13. VANGUARD GROUP INC 739,802 N/A March 31, 2020
14. VANGUARD GROUP INC 732,944 N/A June 30, 2020
15. VANGUARD GROUP INC 732,944 N/A June 30, 2020
16. VANGUARD GROUP INC 732,944 N/A June 30, 2020
17. VANGUARD GROUP INC 732,944 N/A June 30, 2020
18. VANGUARD GROUP INC 732,944 N/A June 30, 2020
19. VANGUARD GROUP INC 732,944 N/A June 30, 2020
20. VANGUARD GROUP INC 732,944 N/A June 30, 2020
21. VANGUARD GROUP INC 732,944 N/A June 30, 2020
22. VANGUARD GROUP INC 732,944 N/A June 30, 2020
23. VANGUARD GROUP INC 732,944 N/A June 30, 2020
24. State Street Corp 625,470 N/A March 31, 2020
25. Invesco Ltd. 476,153 N/A June 30, 2020
26. Invesco Ltd. 476,153 N/A June 30, 2020
27. CREDIT SUISSE AG/ 418,092 N/A June 30, 2020
28. Invesco Ltd. 417,216 N/A Dec. 31, 2019
29. Invesco Ltd. 417,216 N/A Dec. 31, 2019
30. Invesco Ltd. 417,216 N/A Dec. 31, 2019
 


Feedback